- Home
- GUG vs TRVI Comparison
GUG vs TRVI Comparison
Compare GUG & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUG
- TRVI
- Stock Information
- Founded
- GUG 2021
- TRVI 2011
- Country
- GUG United States
- TRVI United States
- Employees
- GUG N/A
- TRVI N/A
- Industry
- GUG Trusts Except Educational Religious and Charitable
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- GUG Finance
- TRVI Health Care
- Exchange
- GUG Nasdaq
- TRVI Nasdaq
- Market Cap
- GUG 470.0M
- TRVI 383.4M
- IPO Year
- GUG N/A
- TRVI 2019
- Fundamental
- Price
- GUG $15.28
- TRVI $6.46
- Analyst Decision
- GUG
- TRVI Strong Buy
- Analyst Count
- GUG 0
- TRVI 8
- Target Price
- GUG N/A
- TRVI $17.56
- AVG Volume (30 Days)
- GUG 108.9K
- TRVI 1.3M
- Earning Date
- GUG 01-01-0001
- TRVI 05-08-2025
- Dividend Yield
- GUG 9.67%
- TRVI N/A
- EPS Growth
- GUG N/A
- TRVI N/A
- EPS
- GUG N/A
- TRVI N/A
- Revenue
- GUG N/A
- TRVI N/A
- Revenue This Year
- GUG N/A
- TRVI N/A
- Revenue Next Year
- GUG N/A
- TRVI N/A
- P/E Ratio
- GUG N/A
- TRVI N/A
- Revenue Growth
- GUG N/A
- TRVI N/A
- 52 Week Low
- GUG $12.71
- TRVI $2.30
- 52 Week High
- GUG $15.06
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- GUG 59.46
- TRVI 56.38
- Support Level
- GUG $14.93
- TRVI $6.37
- Resistance Level
- GUG $15.29
- TRVI $7.24
- Average True Range (ATR)
- GUG 0.24
- TRVI 0.42
- MACD
- GUG 0.06
- TRVI -0.01
- Stochastic Oscillator
- GUG 69.35
- TRVI 50.38
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.